What Is Microdosing a GLP-1? What the Evidence Says

GLP-1 microdosing is more common than many people realize. In a survey of more than 60,000 GLP-1 users, roughly one in seven reported trying it.

People try low-dose GLP-1s for a few main reasons:

• Fewer side effects: Nausea, vomiting, and other GI symptoms are dose-related, so some hope a smaller dose will be easier to tolerate.
• Lower cost: Branded GLP-1s are expensive, and smaller doses can stretch a supply further.
• Longevity and inflammation: Some promote microdosing as a way to get anti-inflammatory or anti-aging benefits without significant weight loss.
• Weight maintenance: Some people use lower doses after reaching a goal weight.

The short answer: the evidence is very limited. Nearly all research on semaglutide and tirzepatide uses standard approved doses. No large randomized trials have tested doses below the approved starter levels for weight loss.

The closest data come from a 2026 study of electronic health records. Researchers looked at patients who stayed on the lowest approved starter doses for at least six months instead of increasing their dose:

• People on low-dose tirzepatide lost an average of 5.5% of body weight at 12 months.
• People on low-dose semaglutide lost an average of 2.2% at 12 months.
• By comparison, matched patients who increased their semaglutide dose lost about 12%.

Keep in mind these were starter doses, not true microdoses. Doses below those levels have even less supporting data.

Claims that GLP-1 microdosing extends lifespan aren’t backed by evidence. Cardiologist Eric Topol has called the trend a craze that isn’t scientifically supported. Standard GLP-1 doses have shown anti-inflammatory effects, but no research shows microdoses do the same.

GLP-1 microdosing is a trend, not an established treatment. If you’re considering a lower dose because of side effects or cost, talk to a licensed healthcare provider. They can adjust your dose safely within approved guidelines and help you weigh the trade-offs. Retatrutide isn’t an option outside clinical trials until it’s approved.

• What is a GLP-1 microdose? A dose below the lowest FDA-approved dose, such as under 0.25 mg of semaglutide or under 2.5 mg of tirzepatide per week.
• Does microdosing semaglutide work for weight loss? There’s little evidence. Even people who stayed on the lowest approved semaglutide dose lost only about 2% of body weight in a year.
• Is microdosing tirzepatide safe? Its safety hasn’t been studied in clinical trials. Risks include dosing errors and unregulated compounded products.
• Can you microdose retatrutide? Retatrutide isn’t FDA-approved and has no approved dose or legitimate retail source. Products sold online are unregulated, and no research supports microdosing it.
• Is GLP-1 microdosing FDA-approved? No. Microdosing falls outside FDA-approved dosing guidelines.

• Epocrates – Is GLP-1 Microdosing Effective? (2026)
• Katie Couric Media – Some GLP-1 Users Are Scaling Back Their Dose
• Money Talks News – Microdosing GLP-1s: The Dangers
• Yahoo News – No Link Between Microdosing Weight-Loss Compounds and Living Longer
• Ro – Microdosing GLP-1s: Semaglutide, Tirzepatide, and Ozempic
• Drugs.com – Retatrutide FDA Approval Status